Soliqua 100-33 (Insulin Glargine/Lixisenatide) — Medicare Part D spending
Sanofi-Aventis · Rank #163 by total Part D spend · CMS data year 2023
Medicare Part D spent $302,998,642 on Soliqua 100-33 (Insulin Glargine/Lixisenatide) in 2023, the #163 drug by total Part D spending out of 3,598 drugs. That worked out to about $59.80 per dosage unit, $1,148 per claim and $5,086 per beneficiary, across 263,822 claims for 59,571 beneficiaries. Average spending per dosage unit rose +5.8% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Soliqua 100-33 (Insulin Glargine/Lixisenatide) spending at a glance (2023)
| Metric | Soliqua 100-33 (Insulin Glargine/Lixisenatide) |
|---|---|
| Total Part D spending (2023) | $302,998,642 |
| Total spending (2022) | $215,943,202 |
| Year-over-year change in total spending | +40.3% |
| Average spending per dosage unit (2023) | $59.80 |
| Change in spend per dosage unit (YoY) | +5.8% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +5.7% |
| Average spending per claim (2023) | $1,148 |
| Average spending per beneficiary (2023) | $5,086 |
| Total claims (2023) | 263,822 |
| Beneficiaries (2023) | 59,571 |
| Total dosage units (2023) | 5,067,178 |
| Manufacturer(s) | Sanofi-Aventis |
| National rank by total spend (of 3,598 drugs) | #163 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $215,943,202 | $302,998,642 | +40.3% |
| Avg spend per dosage unit | $56.51 | $59.80 | +5.8% |
| Avg spend per claim | $1,090 | $1,148 | — |
| Avg spend per beneficiary | $4,831 | $5,086 | — |
| Total claims | 198,066 | 263,822 | — |
| Beneficiaries | 44,696 | 59,571 | — |
How Soliqua 100-33 compares with nearby drugs
Drugs with total Part D spending closest to Soliqua 100-33 (Insulin Glargine/Lixisenatide):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Soliqua 100-33 (Insulin Glargine/Lixisenatide) (this drug, #163) | $302,998,642 | $59.80 | +5.8% |
| Ubrelvy (Ubrogepant) (#161) | $314,663,943 | $104.16 | +3.8% |
| Ninlaro (Ixazomib Citrate) (#162) | $311,982,549 | $4,346.07 | +7.8% |
| Octagam (Immun Globg(IgG)/Malt/IgA Ov50) (#164) | $300,823,932 | $18.28 | +5.0% |
| Radicava Ors (Edaravone) (#165) | $293,678,844 | $271.04 | +2.1% |
| Ezetimibe (#166) | $290,177,168 | $0.57 | -29.0% |
Frequently asked questions
How much does Medicare Part D spend on Soliqua 100-33?
Medicare Part D spent $302,998,642 on Soliqua 100-33 (Insulin Glargine/Lixisenatide) in 2023 (the latest CMS data year), across 263,822 claims for 59,571 beneficiaries. That ranks #163 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Soliqua 100-33?
In 2023, the weighted average Medicare Part D spending per dosage unit for Soliqua 100-33 (Insulin Glargine/Lixisenatide) was $59.80. Compared with 2022 it rose +5.8%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Soliqua 100-33?
CMS attributes Soliqua 100-33 (Insulin Glargine/Lixisenatide) to Sanofi-Aventis in the 2023 Part D spending file. Average spending per claim was $1,148 and per beneficiary $5,086.
Is the Soliqua 100-33 figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20